Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
TransMedics Group $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Gilead Sciences $405 million acquisition of MiroBio
We are advising Gilead Sciences on the transaction
Allakos $75 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Taibang Biologic Group $300 million equity raising
We are advising Taibang Biologic Group in connection with its equity raising by a group of investors
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Legend Biotech $403 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Envision Healthcare and AMSURG $600 million new credit facilities
We advised the agent on an amendment including a $300 million “first out” tranche and on a new $300 million revolver
Revolution Medicines $264.5 million follow-on offering
The shares are listed on Nasdaq
Akeso HK$582 million share placement
We advised Akeso in the placement of new shares
Precigen sale of Trans Ova Genetics to URUS
We are advising Precigen on the transaction